Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, Tibor Csőszi et al.|The Lancet Oncology|2021Cited by 645
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Christopher J. Sweeney, Kobe Yuen et al.|Nature Medicine|2022Cited by 241
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary SiteHidetoshi Hayashi, Kazuhiko Nakagawa, Koji Matsumoto et al.|Journal of Clinical Oncology|2019Cited by 168